# Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

> **NCT00064142** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- AIDS-related Kaposi Sarcoma
- Recurrent Kaposi Sarcoma

## Interventions

- **DRUG:** halofuginone hydrobromide
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00064142
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2006-12
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064142, "Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00064142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*